Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of
allogeneic hematopoietic stem cell transplantation. The investigators try to observe the
efficacy and safety of application of vedolizumab, anti-CD25 monoclonal antibody and rapid
reduction of glucocorticoids in the treatment of grade 3-4 steroid-refractory aGVHD(SR-aGVHD)
with lower gastrointestinal involvement.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Affiliated Hospital of Nantong University The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School The First Affiliated Hospital with Nanjing Medical University